Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Maja Ebert Moltara) .

1 - 10 / 100
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
1.
Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer : single center experience
Janja Ocvirk, Maja Ebert Moltara, Tanja Mesti, Marko Boc, Martina Reberšek, Neva Volk, Jernej Benedik, Zvezdana Hlebanja, 2016, izvirni znanstveni članek

Povzetek: Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim of the study was with the help of the patients% register to determine the safety and efficacy of bevacizumab plus chemotherapy in elderly patients who had previously untreated metastatic colorectal cancer. Patients and methods. The registry of patients with mCRC was designed to prospectively evaluate the safety and efficacy of bevacizumab-containing chemotherapy as well as selection of patients in routine clinical practice. Patient baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected, evaluated and compared according to the age categories. Results. Between January 2008 and December 2010, 210 patients with mCRC (median age 63, male 61.4%) started bevacizumab-containing therapy in the 1st line setting. Majority of the 210 patients received irinotecan-based chemotherapy (68%) as 1st line treatment and 105 patients (50%) received bevacizumab maintenance therapy. Elderly (% 70 years) patients presented 22.9% of all patients and they had worse performance status (PS 1/2, 62.4%) than patients in < 70 years group (PS 1/2, 35.8%). Difference in disease control rate was mainly due to inability to assess response in elderly group (64.6% in elderly and 77.8% in < 70 years group, p = 0.066). The median progression free survival was 10.2 (95% CI, 6.7%16.2) and 11.3 (95% CI, 10.2%12.6) months in elderly and < 70 years group, respectively (p = 0.58). The median overall survival was 18.5 (95% CI, 12.4%28.9) and 27.4 (95% CI, 22.7%31.9) months for elderly and < 70 years group, respectively (p = 0.03). Three-year survival rate was 26% and 37.6% in elderly vs. < 70 years group (p = 0.03). Overall rates of bevacizumab-related adverse events were similar in both groups: proteinuria 21/22 %, hypertension 25/19 %, haemorrhage 2/4 % and thromboembolic events 10/6 %, for elderly and < 70 years group, respectively. Conclusions. In routine clinical practice, the combination of bevacizumab and chemotherapy is effective and welltolerated regimen in elderly patients with metastatic colorectal cancer.
Ključne besede: metastatic colorectal cancer, bevacizumab, chemotherapy, elderly
Objavljeno v DiRROS: 30.04.2024; Ogledov: 143; Prenosov: 36
.pdf Celotno besedilo (620,74 KB)

2.
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Tanja Mesti, Maja Ebert Moltara, Marko Boc, Martina Reberšek, Janja Ocvirk, 2015, izvirni znanstveni članek

Povzetek: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0%2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.
Ključne besede: recurrent malignant glioma, systemic therapy, bevacizumab
Objavljeno v DiRROS: 17.04.2024; Ogledov: 138; Prenosov: 34
.pdf Celotno besedilo (534,06 KB)

3.
Kadar je zdravstveni delavec bolnik ali bolnikov bližnji
Maja Ebert Moltara, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: zdravstveni delavci, bolniki, onkologija
Objavljeno v DiRROS: 27.02.2024; Ogledov: 175; Prenosov: 44
.pdf Celotno besedilo (238,57 KB)

4.
Paliativna oskrba bolnikov z maligno utesnitvijo hrbtenjače
Ana Lina Vodušek, Maja Ebert Moltara, 2023, objavljeni znanstveni prispevek na konferenci

Ključne besede: onkologija, radioterapija, hrbtenjača, maligna utesnitev hrbtenjače
Objavljeno v DiRROS: 12.12.2023; Ogledov: 241; Prenosov: 103
.pdf Celotno besedilo (2,46 MB)
Gradivo ima več datotek! Več...

5.
5. slovenski kongres paliativne oskrbe z mednarodno udeležbo : "Živeti brez strahu"
2023, druge monografije in druga zaključena dela

Ključne besede: terminalni bolniki, umirajoči, zdravstvena oskrba, zborniki
Objavljeno v DiRROS: 23.10.2023; Ogledov: 448; Prenosov: 121
.pdf Celotno besedilo (12,55 MB)

6.
4. slovenski kongres paliativne oskrbe : "Skupaj na pravi poti."
2021, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Ključne besede: terminalni bolniki, umirajoči, zdravstvena oskrba, povzetki, zborniki, elektronske knjige
Objavljeno v DiRROS: 23.10.2023; Ogledov: 369; Prenosov: 144
.pdf Celotno besedilo (11,71 MB)
Gradivo ima več datotek! Več...

7.
Priporočila za obravnavo bolnikov s pljučnim rakom
Martina Vrankar, Nina Boc, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But-Hadžić, Anton Crnjac, Marina Čakš, Dominik Časar, Eva Ćirić, Tanja Čufer, Ana Demšar, Rok Devjak, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik-Kramberger, Maja Ivanetič Pantar, Marija Ivanović, Urška Janžič, Staša Jelerčič, Veronika Kloboves-Prevodnik, Mile Kovačević, Luka Ležaič, Mateja Marc-Malovrh, Katja Mohorčič, Loredana Mrak, Igor Požek, Nina Turnšek, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačić, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar, 2023, strokovni članek

Povzetek: Leta 2019 so bila objavljena Priporočila za obravnavo bolnikov s pljučnim rakom, ki so v slovenski prostor vnesla prepotrebno poenotenje diagnostike in zdravljenja z namenom izboljšanja preživetja bolnikov s pljučnim rakom. Posodobitev Priporočil tri leta po izidu izvirnika prinaša največ novosti v poglavju o sistemskem zdravljenju bolnikov s pljučnim rakom. To kaže na izjemen napredek na področju razumevanja onkogeneze in biologije pljučnega raka ter s tem razvoja novih zdravil. Breme pljučnega raka ostaja veliko, saj je pljučni rak pri nas in v svetu še vedno najpogostejši vzrok smrti zaradi raka. Za vsako peto smrt zaradi raka je odgovoren pljučni rak. Skoraj tretjina bolnikov s pljučnim rakom ne prejme specifičnega onkološkega zdravljenja, bodisi zaradi slabega stanja zmogljivosti, spremljajočih bolezni ali obsega bolezni. Polovica bolnikov ima ob diagnozi razsejano bolezen, zaradi česar izboljšanje preživetja z malimi koraki sledi napredku v zdravljenju bolnikov s pljučnim rakom. Ti podatki nas opominjajo, da se bomo morali za velike premike v obravnavi bolnikov s pljučnim rakom lotiti drugačnih pristopov. Kot najbolj obetavno se ponuja zgodnje odkrivanje bolezni, ko so možnosti ozdravitve pljučnega raka najboljše. Zapisana Priporočila so usmeritev za obravnavo bolnikov s pljučnim rakom. Le s sodobnim multidisciplinarnim pristopom obravnave lahko bolniku ponudimo zdravljenje, ki mu omogoča najboljši izhod prognostično neugodne bolezni.
Ključne besede: pljučni rak, priporočila
Objavljeno v DiRROS: 27.07.2023; Ogledov: 477; Prenosov: 165
.pdf Celotno besedilo (708,18 KB)
Gradivo ima več datotek! Več...

8.
Žalovanje
Marjana Bernot, Polona Ozbič, Maja Ebert Moltara, Nikki Archer, 2023, samostojni strokovni sestavek ali poglavje v monografski publikaciji

Ključne besede: žalovanje, onkologija, bolniki
Objavljeno v DiRROS: 24.05.2023; Ogledov: 473; Prenosov: 110
.pdf Celotno besedilo (205,69 KB)

9.
Kanabinoidi
Jernej Benedik, Slavica Lahajnar, 2023, samostojni strokovni sestavek ali poglavje v monografski publikaciji

Ključne besede: kanabinoidi, onkologija, bolniki
Objavljeno v DiRROS: 24.05.2023; Ogledov: 467; Prenosov: 108
.pdf Celotno besedilo (222,88 KB)

10.
Obravnava umirajočega
Maja Ebert Moltara, Suzana Crljenica, Marjana Bernot, 2023, samostojni strokovni sestavek ali poglavje v monografski publikaciji

Ključne besede: paliativna oskrba, onkologija, bolniki
Objavljeno v DiRROS: 24.05.2023; Ogledov: 362; Prenosov: 147
.pdf Celotno besedilo (214,29 KB)

Iskanje izvedeno v 0.26 sek.
Na vrh